HLA-C and neoplasm: By upregulating the major histocompatibility complex (MHC) class I and II antigen- and cross-presentation pathways, as well as MHC-II expression on classically non-MHC-II-expressing cells, it enhances tumor cell susceptibility to adaptive immune cells.